Although in situ RNA detection techniques have been around for decades, they have largely been ineffective when it comes to distinguishing between highly homologous targets. Lacking the specificity needed to reliably distinguish pathogens whose rRNA are more than 98% similar. Due to this drawback PCR has become the gold standard molecular method for disease profiling at the cost of clinically relevant information regarding the cellular and tissue context, which is lost with PCR's grind-and-bind approach.

ChampDx's proprietary InfectISH™ technology is a novel RNA in-situ hybridization (ISH) assay capable of detecting ribosomal RNA (rRNA) within intact cells and tissue. The combination of its proprietary probe design and amplification scheme ensures that only target-specific signals are amplified and not background noise from non-specific hybridization.